IL144643A0 - Jak-3 inhibitors for treating allergic disorders - Google Patents

Jak-3 inhibitors for treating allergic disorders

Info

Publication number
IL144643A0
IL144643A0 IL14464300A IL14464300A IL144643A0 IL 144643 A0 IL144643 A0 IL 144643A0 IL 14464300 A IL14464300 A IL 14464300A IL 14464300 A IL14464300 A IL 14464300A IL 144643 A0 IL144643 A0 IL 144643A0
Authority
IL
Israel
Prior art keywords
inhibitors
jak
allergic disorders
treating allergic
treating
Prior art date
Application number
IL14464300A
Other languages
English (en)
Original Assignee
Parker Hughes Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parker Hughes Inst filed Critical Parker Hughes Inst
Publication of IL144643A0 publication Critical patent/IL144643A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL14464300A 1999-03-05 2000-03-01 Jak-3 inhibitors for treating allergic disorders IL144643A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/263,420 US6080747A (en) 1999-03-05 1999-03-05 JAK-3 inhibitors for treating allergic disorders
PCT/US2000/005353 WO2000051587A2 (en) 1999-03-05 2000-03-01 Jak-3 inhibitors for treating allergic disorders

Publications (1)

Publication Number Publication Date
IL144643A0 true IL144643A0 (en) 2002-05-23

Family

ID=23001710

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14464300A IL144643A0 (en) 1999-03-05 2000-03-01 Jak-3 inhibitors for treating allergic disorders

Country Status (11)

Country Link
US (8) US6080747A (de)
EP (1) EP1158968B1 (de)
JP (1) JP2002538107A (de)
KR (1) KR20010102514A (de)
AT (1) ATE316785T1 (de)
AU (1) AU3509000A (de)
CA (1) CA2362529A1 (de)
DE (1) DE60025812D1 (de)
IL (1) IL144643A0 (de)
NO (1) NO20014303L (de)
WO (1) WO2000051587A2 (de)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
SK286640B6 (sk) 1998-06-19 2009-03-05 Pfizer Products Inc. Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva
EP1510212A1 (de) * 1998-08-21 2005-03-02 Parker Hughes Institute Verwendung von 4-substituerte Chinazolin-Derivaten zur Herstellung von therapeutischen Mitteln
KR20010089171A (ko) * 1998-08-21 2001-09-29 추후제출 퀴나졸린 유도체
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
CA2392554A1 (en) * 1999-11-30 2001-06-28 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
DE60037345T2 (de) * 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
ATE423120T1 (de) * 2000-06-26 2009-03-15 Pfizer Prod Inc Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
ATE384121T1 (de) * 2000-08-08 2008-02-15 Philadelphia Health & Educatio Verfahren zur kultivierung von menschlichen lungenmastzellen und deren anwendungen
WO2002016352A1 (en) 2000-08-21 2002-02-28 Astrazeneca Ab Quinazoline derivatives
EP1318985A2 (de) * 2000-09-20 2003-06-18 MERCK PATENT GmbH 4-amino chinazolinen
JP2004509876A (ja) * 2000-09-20 2004-04-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ４−アミノ−キナゾリン
US20040034045A1 (en) * 2000-11-29 2004-02-19 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
PE20020958A1 (es) * 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
UY27224A1 (es) * 2001-03-23 2002-10-31 Bayer Corp Inhibidores de la rho-quinasa
US7301023B2 (en) * 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
US7132427B2 (en) * 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
US7829566B2 (en) * 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
US20050043336A1 (en) * 2001-11-03 2005-02-24 Hennequin Laurent Francois Andre Quinazoline derivatives as antitumor agents
PY0228255A (es) * 2001-12-06 2004-06-01 Pfizer Prod Inc Compuestos cristalinos novedosos
JP4505228B2 (ja) * 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
EP1470121B1 (de) * 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidin-derivate als rho kinase inhibitoren
MXPA04007196A (es) * 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7645878B2 (en) * 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
RU2004135386A (ru) * 2002-05-06 2005-07-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Тиадиазолы или оксадиазолы и их применение в качестве ингибиторов протеинкиназы jak
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
NZ539901A (en) * 2002-11-26 2007-09-28 Pfizer Prod Inc Method of treatment of transplant rejection
CA2506432A1 (en) * 2002-12-09 2004-06-24 Robert A. Kirken Methods for selectively inhibiting janus tyrosine kinase 3 (jak3)
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
AU2004253967B2 (en) * 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
UY28441A1 (es) * 2003-07-29 2005-02-28 Astrazeneca Ab Derivados de quinazolina
WO2005012294A1 (en) * 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
ATE395346T1 (de) * 2003-09-16 2008-05-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
EP1664028A1 (de) * 2003-09-16 2006-06-07 AstraZeneca AB Chinazolinderivate als tyrosinkinaseinhibitoren
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
ES2279441T3 (es) * 2003-09-19 2007-08-16 Astrazeneca Ab Derivados de quinazolina.
CN1882570B (zh) * 2003-09-19 2010-12-08 阿斯利康(瑞典)有限公司 喹唑啉衍生物
WO2005030757A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives
EP2210607B1 (de) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamid zur Behandlung von Krebs
US20070123537A1 (en) * 2003-10-06 2007-05-31 Gpc Biotech Ag Quinazoline derivatives for the treatment of herpesviral infections
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
DK1704145T3 (da) * 2004-01-12 2012-09-24 Ym Biosciences Australia Pty Selektive kinaseinhibitorer
CA2929754A1 (en) 2004-04-12 2005-10-27 Sanbio Inc. Cells exhibiting neuronal progenitor cell characteristics
AU2005237254B2 (en) 2004-05-03 2010-02-04 Novartis Ag Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
US7405037B2 (en) * 2004-05-07 2008-07-29 Lonza Walkersville, Inc. Methods and tools for detecting collagen degradation
BRPI0511741A (pt) * 2004-06-04 2008-01-02 Astrazeneca Ab derivado de quinazolina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processo para a preparação de um derivado de quinazolina ou de um sal farmaceuticamente aceitável do mesmo
US9132116B2 (en) * 2004-08-02 2015-09-15 Willowcroft Pharm Inc. Mast cell stabilizers to prevent or treat laminitis
ATE501148T1 (de) 2004-12-14 2011-03-15 Astrazeneca Ab Pyrazolopyrimidinverbindungen als antitumormittel
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
US8258145B2 (en) * 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
KR20070107151A (ko) * 2005-02-26 2007-11-06 아스트라제네카 아베 티로신 키나제 억제제로서의 퀴나졸린 유도체
CA2600745A1 (en) * 2005-03-03 2006-09-08 The Burnham Institute For Medical Research Screening methods for protein kinase b inhibitors employing virtual docking approaches and compounds and compositions discovered thereby
GB0504474D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
JP2008534689A (ja) * 2005-04-05 2008-08-28 ファーマコペイア， インコーポレイテッド 免疫抑制のためのプリン及びイミダゾピリジン誘導体
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
GB0508717D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
BRPI0610876B8 (pt) 2005-06-08 2021-05-25 Rigel Pharmaceuticals Inc composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
ATE488513T1 (de) * 2005-09-20 2010-12-15 Astrazeneca Ab 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
JP2009508917A (ja) * 2005-09-20 2009-03-05 アストラゼネカ アクチボラグ 抗癌剤としてのキナゾリン誘導体
WO2007063293A1 (en) * 2005-12-02 2007-06-07 Astrazeneca Ab Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase
EP1957499A1 (de) * 2005-12-02 2008-08-20 AstraZeneca AB 4-anilinosubstituierte chinazolinderivate als tyrosinkinaseinhibitoren
US8409565B2 (en) * 2006-02-14 2013-04-02 Francesca Levi-Schaffer Therapeutic target and diagnostic marker for asthma and related conditions
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US20090281075A1 (en) * 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
ES2622493T3 (es) * 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
AU2007238608A1 (en) 2006-04-14 2007-10-25 Massachusetts Institute Of Technology Identifying and modulating molecular pathways that mediate nervous system plasticity
TW200837064A (en) * 2006-10-04 2008-09-16 Pharmacopeia Inc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7919490B2 (en) * 2006-10-04 2011-04-05 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
EP1921070A1 (de) * 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
AU2008212999A1 (en) * 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
NZ582188A (en) * 2007-07-11 2012-03-30 Pfizer Pharmaceutical compositions and methods of treating dry eye disorders
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
HUE030912T2 (en) 2008-02-15 2017-06-28 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8063058B2 (en) 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
AU2009238590A1 (en) * 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
JP5739802B2 (ja) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
EP2313397B1 (de) * 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
KR101335843B1 (ko) 2008-08-20 2013-12-02 조에티스 엘엘씨 피롤로[2,3-ｄ]피리미딘 화합물
US8385364B2 (en) * 2008-09-24 2013-02-26 Nec Laboratories America, Inc. Distributed message-passing based resource allocation in wireless systems
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
WO2010093808A1 (en) * 2009-02-11 2010-08-19 Reaction Biology Corp. Selective kinase inhibitors
MY159327A (en) * 2009-02-27 2016-12-25 Ambit Biosciences Corp Jak kinase modulating quinazoline derivatives and methods of use thereof
CN106420756A (zh) * 2009-07-28 2017-02-22 里格尔药品股份有限公司 抑制jak途径的组合物和方法
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
WO2012030948A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
EP2663553B1 (de) * 2010-09-01 2015-08-26 Ambit Biosciences Corporation Chinolin- und isochinolinverbindungen zur verwendung als jak-modulatoren
EP2975027A1 (de) 2010-11-01 2016-01-20 Portola Pharmaceuticals, Inc. Nicotinamide als jak-kinasemodulatoren
MX363551B (es) 2011-11-23 2019-03-27 Portola Pharmaceuticals Inc Star Compuestos derivados de pirazina como inhibidores de cinasa.
WO2014018195A1 (en) * 2012-06-21 2014-01-30 Monsanto Technology Llc Lysis buffer and methods for extraction of dna from plant material
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
WO2014058921A2 (en) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
US20180107782A1 (en) * 2014-01-20 2018-04-19 Stevan Hubbard Atomic model for janus kinase-2 (jak2) and uses thereof
US10045981B2 (en) 2015-11-24 2018-08-14 Jakpharm, Llc Selective kinase inhibitors
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
JP7291077B2 (ja) 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｊａｋファミリーのキナーゼの低分子阻害物質
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib
EP3947737A2 (de) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur vorhersage und vorbeugung von krebs bei patienten mit prämalignen läsionen
EP3955920A1 (de) 2019-04-16 2022-02-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Verwendung von jak-inhibitoren zur behandlung von schmerzhaften erkrankungen mit nav1.7-kanälen
MX2023010642A (es) 2021-03-11 2023-11-28 Janssen Pharmaceutica Nv Lorpucitinib para uso en el tratamiento de trastornos mediados por jak.
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1199768A (en) * 1966-10-31 1970-07-22 Pfizer & Co C Nitrogen Heterocycles and process for their preparation
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4343940A (en) * 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) * 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) * 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
MX9200299A (es) * 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5705625A (en) * 1994-12-15 1998-01-06 The Johns Hopkins University School Of Medicine Nucleic Acid Encoding novel protein tyrosine kinase
US6800649B1 (en) * 1998-06-30 2004-10-05 Parker Hughes Institute Method for inhibiting c-jun expression using JAK-3 inhibitors
KR20010089171A (ko) * 1998-08-21 2001-09-29 추후제출 퀴나졸린 유도체
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines

Also Published As

Publication number Publication date
KR20010102514A (ko) 2001-11-15
NO20014303D0 (no) 2001-09-04
US20020055514A1 (en) 2002-05-09
ATE316785T1 (de) 2006-02-15
US6933300B2 (en) 2005-08-23
US20020165243A1 (en) 2002-11-07
JP2002538107A (ja) 2002-11-12
EP1158968B1 (de) 2006-02-01
AU3509000A (en) 2000-09-21
EP1158968A2 (de) 2001-12-05
US6313130B1 (en) 2001-11-06
NO20014303L (no) 2001-09-04
US6177433B1 (en) 2001-01-23
CA2362529A1 (en) 2000-09-08
WO2000051587A2 (en) 2000-09-08
US6326373B1 (en) 2001-12-04
US20050187233A1 (en) 2005-08-25
US6080747A (en) 2000-06-27
US6080748A (en) 2000-06-27
DE60025812D1 (de) 2006-04-13
WO2000051587A3 (en) 2000-12-21
US6452005B1 (en) 2002-09-17

Similar Documents

Publication Publication Date Title
IL144643A0 (en) Jak-3 inhibitors for treating allergic disorders
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
AP2000001996A0 (en) Heterocyclic inhibitors of P38.
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
TW200626526A (en) Pharmaceutical compositions for the treatment of neoplasms
WO2003032916A3 (en) Organosulfur inhibitors of tyrosine phosphatases
DE602004005814D1 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
PL374443A1 (en) Novel pyrimidineamide derivatives and the use thereof
GB0111186D0 (en) Novel compounds
AU2838101A (en) Use of melatonin for treating androgenetic and diffuse alopecia
GEP20063868B (en) Combination therapy for the treatment of cancer
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
PT1463735E (pt) Imidazo-2,1-b-1,3,4-tiadiazol sulfonamidas
BG105962A (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
IL161501A0 (en) Methods of preventing and treating flavivirus infection in animals
MXPA02010759A (es) Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa.
JO3446B1 (ar) طريقة لمعالجة الأرق الأولي
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
BR0015938A (pt) Uso de antagonistas beta-adrenoceptores para a fabricação de um medicamento para o tratamento de desordens da retina externa
MXPA02005959A (es) Inhibidores de adenosina cinasa para el tratamiento del nervio optico y el bano retiniano.
AU2576901A (en) Agents and methods for the treatment of proliferative diseases